INVENT Fibrosis and INVENT CNS Pharmaceuticals are focused on bringing breakthrough innovative drugs for helping patients with Fibrosis and CNS diseases, respectively. Both INVENTs has created portfolios of strong intellectual property by securing composition-of-matter, process and utility patents. Both INVENT Fibrosis and INVENT CNS Pharmaceuticals are Emerging Growth Companies (EWC). INVENT's patented drug candidates have eliminated potential attrition risk in clinical development. INVENTs' novel, potent, selective and orally active drug candidates offer significantly superior safety, tolerance and drug efficacy in clinical trials.